Bellevue Group Ag Harmony Biosciences Holdings, Inc. Transaction History

Bellevue Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $57,103 - $99,967	1,854 Added 0.31%	598,046 $19.5 Million
Q4 2022 Feb 14, 2023	SELL	$45.4 - $60.91 $2.77 Million - $3.72 Million	-60,996 Reduced 9.28%	596,192 $32.9 Million
Q3 2022 Nov 14, 2022	SELL	$42.06 - $55.45 $1.89 Million - $2.49 Million	-44,880 Reduced 6.39%	657,188 $29.1 Million
Q2 2022 Aug 11, 2022	BUY	$33.54 - $52.15 $19.4 Million - $30.1 Million	577,107 Added 461.83%	702,068 $34.2 Million
Q1 2022 May 13, 2022	BUY	$33.14 - $51.13 $125,932 - $194,294	3,800 Added 3.14%	124,961 $6.08 Million
Q4 2021 Feb 10, 2022	SELL	$34.09 - $43.91 $277,083 - $356,900	-8,128 Reduced 6.29%	121,161 $5.17 Million
Q3 2021 Nov 12, 2021	BUY	$25.68 - $38.61 $3.32 Million - $4.99 Million	129,289 New	129,289 $4.96 Million

243

45.2M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.04B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.